Clinical Trials Sponsored by Pharmacyclics LLC.

Total 10735 results

Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Breast Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
Pharmacyclics LLC.

Terminated

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Lung Cancer

United States, Canada, Russian Federation, Serbia
Pharmacyclics LLC.

Terminated

Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.

Terminated

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

Neoplasm Metastasis | Brain Neoplasms

United States, Canada
Pharmacyclics LLC.

Completed

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.

Completed

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753)

B-Cell Leukemia | B-Cell Lymphoma

United States
Pharmacyclics LLC.

Completed

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Neoplasms by Site | Multiple Myeloma | Hodgkin Disease | Leukemia, Lymphocytic, Chronic | Lymphoma, Non-hodgkin

United States
Pharmacyclics LLC.

Completed

Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

Neoplasms | Hematologic Neoplasms

United States
Pharmacyclics LLC.

Completed

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

Glioma | Glioblastoma | Astrocytoma | Brain Neoplasm | Oligodendroglioma

United States
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Ovarian Neoplasms

United States
Pharmacyclics LLC.

Completed

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm

United States, France, Belgium, Germany, Canada, Netherlands, Austria, Australia
Pharmacyclics LLC.

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Graft Versus Host Disease

United States
Pharmacyclics LLC.

Completed

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.

Completed

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma (PCYC-0403)

Lymphoma | Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Pharmacyclics LLC.

Completed

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

Metastatic Cancer

United States, Canada
Pharmacyclics LLC.

Completed

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Lymphoma | Leukemia | Multiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Lymphocytic

United States
Pharmacyclics LLC.

Completed

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Bronchogenic | Non-Small-Cell Lung Carcinoma

United States
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Adenocarcinoma | Lung Neoplasms | Non-Small-Cell Lung Carcinoma

United States, Canada
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma

United States
Pharmacyclics LLC.

Completed

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Pharmacyclics LLC.

Completed

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Metastatic Renal Cell Carcinoma | Metastatic Colorectal Adenocarcinoma | Advanced Gastric Adenocarcinoma | Advanced Urothelial Carcinoma

United States, Korea, Republic of, Spain, United Kingdom
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Follicular Lymphoma

United Kingdom, Portugal, Taiwan, Spain, Belgium, Netherlands, Israel, United States, Czechia, Italy, France, Hungary, Australia, Poland, Canada, Austria, Russian Federation, Greece, Turkey
Pharmacyclics LLC.

Completed

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Pharmacyclics LLC.

Completed

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Metastatic Pancreatic Adenocarcinoma

Spain, Italy, Korea, Republic of, United States, Belgium, United Kingdom, Germany, France
Pharmacyclics LLC.

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Pharmacyclics LLC.

Completed

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Follicular Lymphoma | B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
Pharmacyclics LLC.

Terminated

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States
Pharmacyclics LLC.

Completed

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large Cell B-lymphoma

United States
Pharmacyclics LLC.

Terminated

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia | Leukemia, Lymphocytic, Chronic

United States
Pharmacyclics LLC.

Completed

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Pancreatic Cancer | Exocrine Pancreatic Cancer | Ductal Adrenocarcinoma

United States
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Gastrointestinal Neoplasms | Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Ovarian Neoplasms

United States
Pharmacyclics LLC.

Completed

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Pharmacyclics LLC.

Terminated

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Head and Neck Cancer | Oropharynx Cancer | Larynx Cancer | Hypopharynx Cancer

United States
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms

United States
Pharmacyclics LLC.
Janssen Pharmaceuticals

Completed

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) (PCYC-1104-CA)

Mantle Cell Lymphoma

United States, United Kingdom, Germany, Poland
Northwell Health
Pharmacyclics LLC.

Terminated

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Richter Syndrome

United States
Pharmacyclics LLC.
Celgene Corporation

Completed

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma Relapsed

United States
Alliance Foundation Trials, LLC.
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | B Cell Lymphoma | Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Diffuse Well-differentiated Lymphocytic Lymphoma | B-Cell Diffuse Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Healthy Volunteer

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Healthy Volunteer

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Italy, Poland, Spain, Czechia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Korea, Republic of, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more

Clinical Trials Sponsored by Pharmacyclics LLC.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations